Ignite Creation Date:
2024-05-05 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00529451
Status:
COMPLETED
Last Update Posted:
2011-03-25
First Post:
2007-09-12
Brief Title:
Safety and Efficacy of Aliskiren 300 mg 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
An Eight Week Double-blind Randomized Multicenter Parallel Group Active-controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to investigate the efficacy safety and tolerability of aliskiren 300 mg 150 mg and 75 mg when compared to ramipril 5 mg in patients with essential hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None